We appreciate the comment by Dr. George D. Vavougios on our recent paper and recognize the importance of clarifying the biological effect of either angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blocker (ARB) on disease phenotypes of COVID-19 with the ongoing pandemic. There is the concern that the use of RAAS inhibitors may upregulate the level of ACE2 or alter its activity which serves as the functional receptor of SARS-CoV-2, thereby enhance viral infectivity and increase disease virulence. However, the data available so far do not support the hypothesis. First, the effects of RAAS inhibitors on ACE2 expression are uncertain. Experiments in animal models report conflicting findings in regard to the effects of ACE/ARB on the expression or activity of tissue ACE2 [
6]. And very few data has been generated in human, especially regarding ACE/ARB on lung-specific expression of ACE2 [
6]. Second, the causal relationship between ACE2 overexpression and viral infectivity or severe COVID-19 has not been established and other receptors or cofactors may be involved in viral infection process. Actually, the use of RAAS inhibitors may be beneficial in patients with COVID-19. It has been demonstrated in the experimental mouse model of SARS-CoV-1 that RAAS blockade alleviates lung injury, perhaps by reducing angiotensin II accumulation in the lung [
7]. Additionally, ACE/ARB is well-recognized in promoting recovery from myocardial injury [
8]. Furthermore, two recent studies provide preliminary evidence supporting the potential benefit of ACE/ARB in patients with COVID-19. One enrolled 476 patients both from Wuhan and outside Wuhan [
9]. In line with our study, the incidence of hypertension was more frequent in critically illed patients than in the moderate group (35.7% vs 20.7%,
p < 0.05). The study showed that ACEI/ARB inhibitors were less used in severe and critically illed groups than mild-moderate groups (6.1% vs 87.9%). Another enrolled a total of 417 cases, with 51 (12.23%) had hypertension [
10]. Only 4 patients (23.5%) taking ACEI or ARB were severe, in contrast to 12 cases (48%) without the use of these agents. Therefore, current data favor a beneficial rather than pathogenic role of ACEI or ARB in COVID-19. If so, we actually underestimate the risk of hypertension in relation to the severe phenotype of COVID-19 when the use of ACEI or ARB is not taken into consideration. Nevertheless, we completely agree with the comment that data with respect to the use of RAAS inhibitors and illness severity of COVID-19 are needed, which should be generated by well-designed, high-quality, and large-scale randomized clinical trials or cohort studies enrolling subjects with multi-ethnicities.